Total Revenues of $610.8 million, Cabozantinib Franchise U.S. Net Product Revenues of $555.0 million -- GAAP Diluted EPS of $0.79, Non-GAAP Diluted EPS of $0.87 -- Announced Additional Stock ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results